Journal
LUNG CANCER
Volume 74, Issue 3, Pages 474-480Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2011.05.004
Keywords
Sunitinib; Carboplatin; Paclitaxel; Non-small cell lung cancer; Maintenance; Phase II
Categories
Funding
- Pfizer Inc.
- Pfizer
- Amgen Inc.
- Cephalon Inc.
- Novartis Pharmaceuticals
- Thar Pharmaceuticals
- Monogram Biosciences
- Oncogene Science
Ask authors/readers for more resources
This open-label, phase II study evaluated the antitumor activity and safety of sunitinib monotherapy as maintenance treatment following first-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Following treatment with standard doublet chemotherapy (paclitaxel and carboplatin), patients received oral sunitinib (starting dose 50 mg/day) in 6-week cycles (Schedule 4/2: 4 weeks on treatment, 2 weeks off treatment) until disease progression, unacceptable toxicity or withdrawal of consent. The primary endpoint was probability of survival at 1 year >= 55%. Of 84 patients who received first-line chemotherapy, 66 (79%) received sunitinib maintenance therapy (median sunitinib cycles started: 2 [range 1-20]). Probability of survival at 1 year was 40.5% (95% confidence interval [CI]: 29.8, 51.0). Median overall survival was 10.4 months (95% CI: 8.0, 12.2). The objective response rate was 27.4% (95% CI: 18.2, 38.2). The most frequently reported all-causality adverse events of any grade during sunitinib maintenance therapy were fatigue/asthenia (55%), diarrhea (36%), and nausea (32%). These data suggest that maintenance therapy may have value in NSCLC, although the primary endpoint of the study was not met. (C) 2011 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available